Why Illumina stock is back in focus

Illumina (ILMN) is back on investor watchlists after first quarter 2026 results topped market expectations, the company raised full year guidance, and management highlighted firm demand in clinical sequencing.

The share price has moved to $139.07, with a 7 day share price return of 9.57% and a 30 day gain of 9.18%, suggesting short term momentum. This compares with a 1 year total shareholder return of 86.60% and weaker 3 and 5 year total shareholder returns.

If Illumina's clinical sequencing momentum has your attention, it could be a good moment to see what else is moving in healthcare AI through our 35 healthcare AI stocks

After an 86.60% 1 year total return, a value score of 3, an intrinsic discount of 18.22% and a share price sitting almost level with the average analyst target, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth?

Most Popular Narrative: 2.2% Overvalued

Illumina's most followed narrative pegs fair value at $136.11, slightly below the last close at $139.07, putting a small premium on the current price.

Ongoing innovation, multiomics expansion, and operational efficiency are described as enhancing gross margins and creating new growth opportunities. Strategic expansion into multiomics, notably the planned acquisition of SomaLogic and integration of proteomics capabilities, is viewed as creating incremental growth opportunities by increasing the breadth of Illumina's data and platform offerings, which the narrative states will contribute to future revenue and operating margin expansion.

Want to see what sits behind that premium? The narrative highlights steady revenue increases, higher profitability, and a future earnings multiple that assumes solid execution and adoption.

Result: Fair Value of $136.11 (OVERVALUED)

However, that premium view can quickly be tested if research budgets stay tight or if China related regulation and competition pressure Illumina's pricing power.

Another View: DCF Sees More Room

The most followed narrative says Illumina is about 2.2% overvalued at $139.07, but the SWS DCF model points the other way, with a future cash flow value of $170.05 and the stock trading at an 18.2% discount. Which story do you think fits your expectations better?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Illumina for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals on value and expectations, it makes sense to move fast, review the full picture, and weigh up both sides of the story using our 3 key rewards and 1 important warning sign

Looking for more investment ideas?

Illumina might be front of mind today, but some of the most interesting opportunities often sit just off your radar, so do not miss what else is setting up.

• Target potential mispricings by scanning companies that combine quality and attractive valuations through our 51 high quality undervalued stocks.
• Strengthen your watchlist with businesses that pair robust finances and staying power using the solid balance sheet and fundamentals stocks screener (45 results).
• Spot potential early stage opportunities before they hit the mainstream by checking the screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.